Literature DB >> 28117119

Gadolinium Contrast Enhancement Improves Confidence in Diagnosing Recurrent Soft Tissue Sarcoma by MRI.

Shinn-Huey S Chou1, Daniel S Hippe1, Amie Y Lee1, Kurt Scherer1, Jack A Porrino1, Darin J Davidson1, Felix S Chew1, Alice S Ha2.   

Abstract

RATIONALE AND
OBJECTIVES: To determine how utilization of postgadolinium magnetic resonance imaging (MRI) influenced reader accuracy and confidence at identifying postoperative soft tissue sarcoma (STS) recurrence among readers with various levels of expertise.
MATERIALS AND METHODS: This retrospective study was institutional review board approved and Health Insurance Portability and Accountability Act compliant. Postoperative MRI from 26 patients with prior STS resection (13 patients with confirmed recurrence, 13 without recurrence) was reviewed. Four blinded readers of varying expertise (radiology resident, fellow, attending, and orthopedic oncologist) initially evaluated only the precontrast images and rated each MRI for recurrence on a 5-point confidence scale. Assessment was repeated with the addition of contrast-enhanced sequences. Diagnostic accuracy based on confidence ratings was evaluated using the area under the receiver operating characteristic curve (AUC). Changes in confidence ratings were calculated using Wilcoxon signed-rank test.
RESULTS: All readers demonstrated good diagnostic accuracy both with and without contrast-enhanced images (AUC >0.98 for each reader). When contrast-enhanced images were made available, the resident recorded improved confidence with both assigning (P = 0.031) and excluding recurrence (P = 0.006); the fellow showed improved confidence only with assigning recurrence (P = 0.015); and the surgeon showed improved confidence in excluding recurrence (P = 0.003). The addition of contrast-enhanced images did not significantly influence the diagnostic confidence of the attending radiologist.
CONCLUSIONS: Diagnostic accuracy of MRI was excellent in evaluating postoperative STS recurrence, and reader confidence improved depending on expertise when postgadolinium imaging was included in the assessment.
Copyright © 2017 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Soft tissue sarcoma; gadolinium; magnetic resonance imaging; reader confidence; recurrence

Mesh:

Substances:

Year:  2017        PMID: 28117119     DOI: 10.1016/j.acra.2016.12.010

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  6 in total

Review 1.  Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy.

Authors:  Nisreen S Ezuddin; Juan Pretell-Mazzini; Raphael L Yechieli; Darcy A Kerr; Breelyn A Wilky; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2018-05-21       Impact factor: 2.199

2.  Undifferentiated pleomorphic sarcoma: indolent, tail-like recurrence of a high-grade tumor.

Authors:  Justin S Alpert; Patrick Boland; Meera Hameed; David M Panicek
Journal:  Skeletal Radiol       Date:  2017-09-20       Impact factor: 2.199

3.  Gadolinium-based Contrast Agents Improve Detection of Recurrent Soft-Tissue Sarcoma at MRI.

Authors:  Behrang Amini; William A Murphy; Tamara Miner Haygood; Rajendra Kumar; Kevin W McEnery; John E Madewell; Bilal M Mujtaba; Wei Wei; Colleen M Costelloe
Journal:  Radiol Imaging Cancer       Date:  2020-03-27

4.  Lipomatous Tumors: A Comparison of MRI-Reported Diagnosis with Histological Diagnosis.

Authors:  Tobias M Ballhause; Alexander Korthaus; Martin Jahnke; Karl-Heinz Frosch; Jin Yamamura; Tobias Dust; Carsten W Schlickewei; Matthias H Priemel
Journal:  Diagnostics (Basel)       Date:  2022-05-21

5.  Local recurrence of soft tissue sarcoma: a radiomic analysis.

Authors:  Alberto Stefano Tagliafico; Bianca Bignotti; Federica Rossi; Francesca Valdora; Carlo Martinoli
Journal:  Radiol Oncol       Date:  2019-09-24       Impact factor: 2.991

6.  Diagnostic value of MRI for detecting recurrent soft-tissue sarcoma in a long-term analysis at a multidisciplinary sarcoma center.

Authors:  Olav Jansen; Marcus Both; Sam Sedaghat; Maya Sedaghat; Jens Meschede
Journal:  BMC Cancer       Date:  2021-04-13       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.